Company / Shareholders' Equity
Olema Pharmaceuticals, Inc. Shareholders' Equity History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$409.0M
FY2024
5-year range
$197.5M / $409.0M
FY2020-FY2024
Trend
+61.1%
vs FY2023
Sector context
#107 of 213
Health Care
What the data says
At $409M, Olema Pharmaceuticals, Inc.'s shareholders' equity ranks #107 of 213 in the Health Care sector. Improved from $198M to $409M over the past 2 years.
Based on SEC 10-K filings.
$409M in FY2024 with a 3-year CAGR of +12.8%.
Improved from $198M to $409M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +12.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 213 in Health CareTop 50% of 213This company $409.0M Sector average $2.5B
▼
-84.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +12.8%, indicating consistent growth.
- In FY2024, shareholders' equity increased 61.1% year-over-year.
- Ranks #107 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $409.0M | +61.1% |
| FY2023 | $253.9M | +28.5% |
| FY2022 | $197.5M | -30.6% |
| FY2021 | $284.6M | -15.8% |
| FY2020 | $338.1M | +3291.8% |
| FY2019 | -$10.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026